Sugi Predict

Sugi Predict / Targets / LPAR3

LPAR3

Lysophosphatidic acid receptor 3 · Q9UBY5 · LPAR3 on Sugi Atlas →

120,877 patent compounds predicted against LPAR3, 66,269 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Thiophosphoric Acid Dodecyl Ester Thiophosphoric Acid Dodecyl Ester (SCHEMBL40052) 1.00 19/20
SCHEMBL40320 SCHEMBL40320 1.00 19/20
SCHEMBL40048 SCHEMBL40048 0.75 19/20
SCHEMBL39671 SCHEMBL39671 0.60 16/20
SCHEMBL52629 SCHEMBL52629 0.53 16/20
SCHEMBL51687 SCHEMBL51687 0.55 15/20
SCHEMBL4142 SCHEMBL4142 0.42 15/20
SCHEMBL29136 SCHEMBL29136 1.00 14/20
SCHEMBL27821 SCHEMBL27821 0.95 14/20
SCHEMBL37004 SCHEMBL37004 0.95 14/20
SCHEMBL40063 SCHEMBL40063 0.67 14/20
SCHEMBL40088 SCHEMBL40088 0.67 14/20
SCHEMBL5105 SCHEMBL5105 0.38 14/20
SCHEMBL3970 SCHEMBL3970 0.38 13/20
Bms-986020 Bms-986020 (SCHEMBL14590) 0.74 12/20
SCHEMBL8005 SCHEMBL8005 0.68 12/20
SCHEMBL8006 SCHEMBL8006 0.68 12/20
SCHEMBL52511 SCHEMBL52511 0.60 12/20
SCHEMBL52599 SCHEMBL52599 0.58 12/20
SCHEMBL51678 SCHEMBL51678 0.57 12/20

Clinical trials — most relevant to LPAR3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis PHASE4COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) PHASE1/PHASE2COMPLETED
Repurposing Siponimod for Alzheimer's Disease PHASE2RECRUITING
Psychopharmacology for Cocaine Dependence - Buspirone PHASE2COMPLETED
Assessment of Coronary Plaque Composition PHASE1COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A EARLY_PHASE1COMPLETED
Autotaxin (ATX) as a Marker for Breast Cancer nanUNKNOWN
The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer nanCOMPLETED
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease nanRECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans. nanCOMPLETED
Clinical Study Evaluating the Effect of Losartan nanRECRUITING
Lysophosphatidic Acid / Autotaxin Axis in Rheumatoid Lung Disease nanUNKNOWN
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Prospective Monocentric Clinical-biological Database nanRECRUITING
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LPAR3 binder may also engage these)

ProteinNameSimilarity
Q9EQ31 — 1.000 Q9EQ31 →
Q8K5E0 — 0.999 Q8K5E0 →
LPAR1 Lysophosphatidic acid receptor 1 0.997 landscape →
Q9PU17 — 0.995 Q9PU17 →
Q28031 — 0.991 Q28031 →
P61793 — 0.990 P61793 →
Q9PU16 — 0.989 Q9PU16 →
P61794 — 0.988 P61794 →
P46628 — 0.984 P46628 →
Q9I8K8 — 0.981 Q9I8K8 →
P47752 — 0.976 P47752 →
O97504 — 0.976 O97504 →
P70596 — 0.975 P70596 →
MC5R Melanocortin receptor 5 0.975 landscape →
P34974 — 0.975 P34974 →
P35345 — 0.975 P35345 →
P56450 — 0.974 P56450 →
P52592 — 0.974 P52592 →
MC2R Adrenocorticotropic hormone receptor 0.974 landscape →
MC4R Melanocortin receptor 4 0.974 landscape →
Q8HXX3 — 0.973 Q8HXX3 →
GPR52 G-protein coupled receptor 52 0.973 landscape →
Q9JL06 — 0.973 Q9JL06 →
Q61121 — 0.973 Q61121 →
P70115 — 0.972 P70115 →
Q9TU77 — 0.972 Q9TU77 →
Q15760 — 0.972 Q15760 →
P56451 — 0.972 P56451 →
P41149 — 0.972 P41149 →
Q0Z8I9 — 0.972 Q0Z8I9 →